BioMarin Pharmaceutical Securities Litigation

This official website is maintained by the Notice Administrator supervised by Lead Counsel in the action entitled In re BioMarin Pharmaceutical Inc. Securities Litigation, Case 3:20-cv-06719-WHO (N.D. Cal.) (the “Action”) pending in the United States District Court for the Northern District of California.

The information contained on this web page is only a summary of information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys’ Fees and Litigation Expenses (“Notice”), which you can access by clicking here. Since this website is just a summary, you should review the Notice for additional details.

The Court-appointed Lead Plaintiff Arbejdsmarkedets Tillægspension (“Lead Plaintiff”), on behalf of itself and the Settlement Class, has settled the Action for $39,000,000 in cash (“Settlement”).

On November 8, 2023, the Court held a hearing to consider final approval of the Settlement and other matters. On November 14, 2023, the Court entered a final order approving the Settlement and Plan of Allocation and Lead Counsel’s motion for attorney's fees and litigation expenses, and a final Judgment.

The claims administration concluded in April 2024. On April 15, 2024, Lead Counsel filed a Motion for Approval of Distribution Plan seeking the Court’s permission to distribute the net settlement fund to Court-approved eligible claimants. On May 3, 2024, the Court granted permission for the net settlement fund to be distributed. The initial distribution of funds occurred on June 7, 2024.

If you have questions, you may call the BioMarin Pharmaceutical Securities Settlement Helpline at (877) 390-3369 or email